Rhumbline Advisers Sells 19,829 Shares of OmniAb, Inc. (NASDAQ:OABI)

Rhumbline Advisers trimmed its holdings in OmniAb, Inc. (NASDAQ:OABI) by 11.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 153,812 shares of the company’s stock after selling 19,829 shares during the quarter. Rhumbline Advisers owned about 0.11% of OmniAb worth $544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Barclays PLC increased its stake in shares of OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock worth $606,000 after acquiring an additional 109,236 shares in the last quarter. FMR LLC increased its stake in shares of OmniAb by 10.6% in the 3rd quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after acquiring an additional 13,324 shares in the last quarter. Atria Investments Inc bought a new position in shares of OmniAb in the 3rd quarter worth about $148,000. Murchinson Ltd. bought a new position in shares of OmniAb in the 3rd quarter worth about $4,230,000. Finally, State Street Corp increased its stake in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other OmniAb news, insider Charles S. Berkman sold 8,215 shares of OmniAb stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total value of $30,231.20. Following the completion of the sale, the insider now owns 364,131 shares of the company’s stock, valued at approximately $1,340,002.08. The trade was a 2.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew W. Foehr sold 13,964 shares of OmniAb stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $51,387.52. Following the completion of the sale, the chief executive officer now directly owns 3,798,682 shares of the company’s stock, valued at approximately $13,979,149.76. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,260 shares of company stock valued at $376,601. Company insiders own 8.60% of the company’s stock.

OmniAb Trading Up 0.6 %

NASDAQ:OABI opened at $3.40 on Friday. OmniAb, Inc. has a 12 month low of $3.10 and a 12 month high of $5.72. The company has a market cap of $480.13 million, a PE ratio of -5.48 and a beta of -0.14. The company has a 50 day simple moving average of $3.46 and a two-hundred day simple moving average of $3.85.

Analysts Set New Price Targets

A number of analysts have weighed in on OABI shares. Benchmark restated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.